Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-05-02
2006-05-02
Lewis, Patrick (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S042000, C514S045000, C514S049000
Reexamination Certificate
active
07037900
ABSTRACT:
Compositions and methods are provided for prevention and clinical treatment of various forms of graft-versus-host disease (GVHD) by using inhibitors of adenosine deaminase (ADA). In particular, various formulations and dosing regimens of ADA inhibitors such as pentostatin are provided for the treatment of humans in vivo as well as for ex vivo conditioning of organ transplants in order to specifically suppress T-lymphocyte mediated immune responses while minimizing systemic toxicity of the drug.
REFERENCES:
patent: 5635156 (1997-06-01), Ildstad
patent: 5800539 (1998-09-01), Waller
patent: 5876692 (1999-03-01), Ildstad
patent: 5916910 (1999-06-01), Lai
patent: 6174873 (2001-01-01), Wrenn, Jr.
patent: 6258357 (2001-07-01), Spanner
Trotta et al. Cancer Research, 1981, vol. 41, pp. 2189-2196.
Akpek “Graft-Versus-Host Disease (GVHD) An Evidence-Based Management Guidelines”, Turk. J. Haematol. (2003), vol. 20(3), pp. 123-142.
JF Seymour et al., Response Duration And Recovery of CD4+ Lymphocytes Following Deoxycoformaycin in Intereron- α -resistant Hairy Cell Leukemia: 7-year Follow-Up, Leukemia (1997) 11. pp. 42-47.
G. Dighiero, “Potential Immunological Action of Purine Nucleoside Analogues”, Drugs 47 (Suppl. 6) 1994, pp. 57-62.
Eric H. Krout et al., “Immunosuppressive Effects of Pentostatin”, Journal of Clinical Oncology, vol. 8, No. 5 (May 1990) pp. 848-855.
Joshua Epstein et al., “Prevention of Graft-Versus-Host Disease in Allogeneic Bone Marrow Transplantation by PreTreatment With 2′-Deoxycoformycin”, International Society for Experimental Hematology (1986), pp. 845-849.
Paul P. Trotta et al., “Specific Immunosuppressive Effects of Constant Infusion of 2-Deoxycoformycin,” Cancer Research, Jun. 1981, pp. 2189-2196.
Appelbaum, F., “Allogeneic Stem-Cell Transplantation for Hematological Malignancies”, 1 ed.Medical Management of Hematological Malignant Diseases,ed. E. Freireich. vol. 1. 1998, New York: Marceil Dekker. 572.
Armitage, J., “Bone Marrow Transplantation”,The New England Journal of Medicine,(1994). 330(12):827-838.
Bagasra, O. et al., “Adenosine-deaminase-associated immunodeficiency. I. Differential sensitivities of lymphocyte subpopulations exposed to 2-deoxycoformycin in vivo”,Clinical&Experimental Immunology,(1992), 88(3):383-388.
Beatty, P. et al., “Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies”,Transplantation,(Feb. 1991), 51(2):443-447.
Bolanos-Meade, J. et al., “Pentostatin in steroid-refractory acute graft-versus-host disease”,Journal of Clinical Oncology,(Apr. 20, 2005), 23(12):2661-2668.
Catovsky, D. “Clinical experience with 2′-deoxycoformycin”,Hematology&Cell Therapy,(1996), 38(S2):S103-S107.
Catovsky; D. et al., “Long term results with 2′deoxycoformycin in hairy cell leukemia”,Leukemia&Lymphoma,(1994). 14(S1):109-113.
Cummings, F.J. et al., “Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease”,Journal of Clinical Oncology,(Apr. 1991), 9(4):565-571.
Epstein J. et al., “Prevention of graft-versus-host disease in allogeneic bone marrow transplantation by pretreatment with 2′-deoxycoformycin”,Experimental Hematology,1986. 14(9): p. 845-849.
Ferrara, J., “Cytokine Inhibitors and Graft-versus-Host Disease”,Annals New York Academy of Sciences,(Dec. 29,1995), 770:227-236.
Foss, F.M. et al., “Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sezary syndrome”,Journal of Clinical Oncology,(Dec. 1987), 10(12):1907-1913.
Giblett, E.R. et al., “Adenosine-deaminase Deficiency in Two Patients With Severely Impaired Immunity”,Lancet,(Nov. 18, 1972). 2:1067-1069.
Grever, M. et al., “Optimal treatment for untreated patients with hairly cell leukemia?”, 1996 ASCO Abstract Form,Journal of Clinical Oncology,(Oct. 1995), 13(10):2677-2679.
Grever M. et al., “Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study”, Comment in:J Clin Oncol.,(Oct. 13, 1995), 13(10):2677-2679.
Grever, M. et al., “Low dose doxycoformycin in lymphoid malignancy”,Journal Clinical Oncology,(Sep. 1985), 3(9):1196-1201.
Grever, M.R. et al., “Clinical Pharmacokinetics of 2-Deoxycoformycin in Renal Impairment”,Proceedings of ASCO,(1993), 12(361):140.
Grever, M.R. et al., “Inhibition of K and NK Lymphocyte Cytotoxicity by an Inhibitor of Adenosine Deaminase and Deoxyadenosine”,The Journal Of Immunology,(Dec. 1982), 129(6):365-369.
Khouri, I.F. et al., “Allogeneic blood or marrow transplantation for chronic lymphocytic leukemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease”,British Journal of Hematology,(May 1997), 97(2):466-473.
Kolb, H-J et al., “Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients”,Blood,(Sep. 1, 1995), 86(5):2041-2050.
Kraut, E.H. et al., “Immunosuppressive effects of pentostatin”,Journal of Clinical Oncology,(1990), 8(5):848-855.
Kraut, E.H. et al., “Low-Dose Deoxycoformycin in the Treatment of Hairy Cell Leukemia”,Blood,(1986). 68(5):1119-1122.
Kraut, E.H. et al., “Pentostatin in the Treatment of Advanced Hairy Cell Leukemia”,Journal of Clinical Oncology,(1989), 7(2):168-172.
Lee, S.J., “New approaches for preventing and treating chronic graft-versus-host disease”,Blood,(Jun. 2005), 105(11):4200-4206.
Margolis, J. et al., ASH (1999),Blood,94 # 10 Suppl 1 abstract 4878.
Margolis, J. et al., ASH (2000),Blood96 #11 abstract 1723.
Martin, P.J. et al., “A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment”,Blood,(Oct. 15, 1990), 76(8):1464-1472.
Martin, P.J. et al., “A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment”,Blood,(Apr. 15, 1991), 77(8):1821-1828.
Monfardini, S. et al., “Pentostatin (2′-deoxycoformycin, dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas: phase II study of the EORTC Early Clinical Trials Group”,Oncology,1996. 53(2):163-168.
Nash, R.A. et al., “Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate”,Blood,(Oct. 1, 1992), 80(7):1838-1845.
Or, R. et al., “Fludarabine monophosphate reduces the incidence and severity of graft-versus-host disease in a murine model of bone marrow transplantation”,Blood,(Jul. 1, 1997), 90(1):471-476.
Przepiorka, D. et al., “Consensus Conference on Acute GVHD Grading”,Bone Marrow Transplantation,(Jun. 1995), 15(6):825-828.
Ruers, T.J.M. et al., “Inhibition of Lymphocyte-Specific Enzymes: A Promising Approach for Selective Immunosuppression”,Transplantation Proceedings,(Feb. 1987), 19(1):1287-1289.
Saven, A. et al., “Newer purine analogues for the treatment of hairy-cell leukemia”,New England Journal of Medicine,(Mar. 10, 1994). 330(10):691-697.
Seymour, J.F. et al., “Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year follow-up”,Leukemia,(1997), 11(1):42-47.
Steis, R.G. et al., “Kinetics of recovery of CD4+ T cells in peripheral blood of deoxycoformycin-treated patients”,Journal of the National Cancer Institute,(Nov. 20, 1991), 83(22):1678-1679.
Urba, W.J. et al., “Deoxycoformycin-Induced Immunosuppression in Patients With Hairy Cell Leukemia”,Blood,(Jan. 1989), 73(1):38-46.
Vogelsang, G. et al., “Graft-Versus-Host Disease
DiMartino Jorge
Nelson John Tippett
Lewis Patrick
SuperGen, Inc.
Wilson Sonsini Goodrich & Rosati
LandOfFree
Composition and method for treating graft-versus-host disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition and method for treating graft-versus-host disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition and method for treating graft-versus-host disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3652467